ArticleCureus2025
Charting New Territory With a Novel WHO Provisional Category: A Case Study of a Low-Grade Oncocytic Tumor (LOT) in the Kidney.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rosy Cells with a Rocky Core: Low-Grade Oncocytic Tumor with Osseous Metaplasia.Journal of kidney cancer and VHL · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A low-grade oncocytic tumor of the kidney (LOT) is a distinctive entity categorized under the 2022 World Health Organization (WHO) classification as "Other oncocytic tumors of the kidney." It represents a unique subset of oncocytic tumors, distinct from oncocytoma and chromophobe renal cell carcinoma. Characterized by bland oncocytic cells that diffusely express CK7 and lack CD117 expression, LOT typically manifests as a solitary, small lesion with a low stage. Available data suggest that LOT follows an indolent clinical course. Herein, we present a case of LOT in a 64-year-old male with a favorable course at a one-year follow-up. Understanding the clinical, morphological, and immunophenotypic features of LOT is paramount for accurate identification and characterization. This knowledge facilitates more conservative surgical and clinical management, optimizing patient care and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.